Sales agreement with BioVectra
BioVectra Inc. and Catalys announced today that they have reached an agreement to represent BioVectra’s custom manufacturing services and bioprocess reagents in the territory of France.
BioVectra and Catalys will work together, with Catalys providing on the ground field sales and consultation to the French pharmaceutical and biotechnology client base for BioVectra products and services.
About BioVectra Inc.:
BioVectra is a supplier to the global pharmaceutical industry, operating from three FDA-inspected facilities in Prince Edward Island, Canada. The company is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules. BioVectra has submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada. These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product.
To know more about BioVectra please visit the following links :
And do not hesitate to contact us for any request concerning Biovectra.
